ResearchIn-Press PreviewImmunology Open Access | 10.1172/jci.insight.176166
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Ma, G. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Crowley, A. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Heyndrickx, L. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Rogiers, I. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Parthoens, E. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Van Santbergen, J. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Ober, R. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Bobkov, V. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by de Haard, H. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Ulrichts, P. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Hofman, E. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Louagie, E. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Balbino, B. in: JCI | PubMed | Google Scholar
1Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2argenx BV, Gent, Belgium
3argenx BV, Ghen, Belgium
4Department of Biomedical Molecular Biology, Center for Inflammation Researc, VIB BioImaging Core, Zwijnaarde, Belgium
5argenxn BV, Gent, Belgium
6argenx BV, Zwijnaarde, Belgium
Find articles by Ward, E. in: JCI | PubMed | Google Scholar
Published May 7, 2024 - More info
The homeostasis of immunoglobulin G (IgG) is maintained by the neonatal Fc receptor, FcRn. Consequently, antagonism of FcRn to reduce endogenous IgG levels is an emerging strategy for treating antibody-mediated autoimmune disorders using either FcRn-specific antibodies or an engineered Fc fragment. For certain FcRn-specific antibodies, this approach has resulted in reductions in the levels of serum albumin, the other major ligand transported by FcRn. Cellular and molecular analyses of a panel of FcRn antagonists have been carried out to elucidate the mechanisms leading to their differential effects on albumin homeostasis. These analyses have identified two processes underlying decreases in albumin levels during FcRn blockade: increased degradation of FcRn and competition between antagonist and albumin for FcRn binding. These findings have potential implications for the design of drugs to modulate FcRn function.